➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Dow
McKinsey
Boehringer Ingelheim
Express Scripts
AstraZeneca
Colorcon

Last Updated: June 25, 2021

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR SOLRIAMFETOL

« Back to Dashboard

All Clinical Trials for Solriamfetol

Trial ID Title Status Sponsor Phase Start Date Summary
NCT03868943 Solriamfetol in Improving Sleep in Patients With Grade II-IV Glioma Not yet recruiting National Cancer Institute (NCI) Phase 2 2019-05-01 This phase II trial studies the side effects of solriamfetol in improving sleep in patients with grade II-IV glioma. Solriamfetol is a wakefulness-promoting drug. Giving solriamfetol may improve sleep, memory, fatigue, mood, or quality of life in patients with brain tumors (gliomas).
NCT03868943 Solriamfetol in Improving Sleep in Patients With Grade II-IV Glioma Not yet recruiting Wake Forest University Health Sciences Phase 2 2019-05-01 This phase II trial studies the side effects of solriamfetol in improving sleep in patients with grade II-IV glioma. Solriamfetol is a wakefulness-promoting drug. Giving solriamfetol may improve sleep, memory, fatigue, mood, or quality of life in patients with brain tumors (gliomas).
NCT04602936 Solriamfetol in Binge Eating Disorder Not yet recruiting Jazz Pharmaceuticals Phase 4 2020-11-15 The goal of this project is to evaluate the efficacy and tolerability of the novel dopamine and norepinephrine reuptake inhibitor (DNRI) solriamfetol in the treatment of binge eating disorder (BED).
NCT04602936 Solriamfetol in Binge Eating Disorder Not yet recruiting Lindner Center of HOPE Phase 4 2020-11-15 The goal of this project is to evaluate the efficacy and tolerability of the novel dopamine and norepinephrine reuptake inhibitor (DNRI) solriamfetol in the treatment of binge eating disorder (BED).
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Solriamfetol

Condition Name

Condition Name for Solriamfetol
Intervention Trials
Excessive Sleepiness 1
Excessive Daytime Somnolence 1
Shift-work Disorder 1
Chronic Fatigue Syndrome 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Solriamfetol
Intervention Trials
Sleepiness 2
Feeding and Eating Disorders 1
Disorders of Excessive Somnolence 1
Hyperkinesis 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Solriamfetol

Trials by Country

Trials by Country for Solriamfetol
Location Trials
United States 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Solriamfetol
Location Trials
Massachusetts 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Solriamfetol

Clinical Trial Phase

Clinical Trial Phase for Solriamfetol
Clinical Trial Phase Trials
Phase 4 4
Phase 2/Phase 3 1
Phase 2 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Solriamfetol
Clinical Trial Phase Trials
Not yet recruiting 6
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Solriamfetol

Sponsor Name

Sponsor Name for Solriamfetol
Sponsor Trials
Jazz Pharmaceuticals 3
Lindner Center of HOPE 1
Wake Forest University Health Sciences 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Solriamfetol
Sponsor Trials
Other 5
Industry 3
NIH 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Merck
Boehringer Ingelheim
McKesson
Moodys
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.